Details der Publikation - Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active antiretroviral treatment (HAART) in HIV-infected hemophilia patients

Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active antiretroviral treatment (HAART) in HIV-infected hemophilia patients / V. Daniel, C. Süsal, A. Melk, R. Weimer, M. Kröpelin, R. Zimmermann, A. Huth-Kühne, C. Uhle, G. Opelz

BACKGROUND AND OBJECTIVES: Human immunodeficiency virus (HIV)-induced immune complex load on circulating CD4+ blood lymphocytes is associated with dysfunction and depletion of CD4+ lymphocytes and with increased monocyte/macrophage function. It was investigated whether HAART reduces both the viral load in plasma and the number of immune complex-coated CD4+ lymphocytes in the blood, and whether CD4+ counts are associated with viral load and/or immune complex load. MATERIALS AND METHODS: Twelve HIV+ hemophilia patients before and after conversion to HAART (group 1); eight HIV+ hemophilia patients without antiretroviral therapy (group 2). HIV-1 RNA copies in plasma using NASBA/Nuclisens kits; CD4+ lymphocytes coated in-vivo with immune complexes using flowcytometry on whole blood samples; in-vitro responses of immune complex-coated T lymphocytes in cell culture assays. RESULTS: After conversion to HAART there was a significant reduction of viral load, CD4+ gp120+, CD4+ IgM+, and CD4+ IgG+ circulating blood lymphocytes and plasma neopterin, paralleled by a significant increase of CD4+ and CD8+ counts. The percentage of immune complex-coated CD4+ lymphocytes of converted patients was significantly associated with CD4+ counts, in-vitro responses to concanavalin A (Con A), pokeweed mitogen (PWM), phytohaemagglutinin (PHA), anti-CD3 and pooled allogeneic stimulator cells, and with plasma neopterin levels. CONCLUSION: HAART reduces viral load and HIV-induced immune complex load on circulating CD4+ blood lymphocytes. The results of this study can be interpreted to suggest that HAART increases CD4+ lymphocyte counts in part by counteracting HIV-induced autoimmune phenomena..

Medienart:	E-Artikel

Erscheinungsjahr:	1999
Erschienen:	1999

Enthalten in:	Zur Gesamtaufnahme - volume:69
Enthalten in:	Immunology letters - 69(1999), 2, Seite 283-289

Sprache:	Englisch

Beteiligte Personen:	Daniel, Volker [VerfasserIn] Süsal, Caner [VerfasserIn] Melk, Anette [VerfasserIn] Weimer, Rolf [VerfasserIn] Kröpelin, M. [VerfasserIn] Zimmermann, R. [VerfasserIn] Huth-Kühne, A. [VerfasserIn] Uhle, C. [VerfasserIn] Opelz, Gerhard, 1944- [VerfasserIn]

Links:	Volltext [lizenzpflichtig] Volltext [lizenzpflichtig]

Themen:	Anti-HIV Agents Antibodies, Anti-Idiotypic Antigen-Antibody Complex Autoantibodies Autoimmunity CD4-Positive T-Lymphocytes Concanavalin A Drug Therapy, Combination HIV Envelope Protein gp120 HIV Infections HIV Protease Inhibitors Hemophilia A Humans Immunoglobulins Lymphocyte Activation Lymphocyte Culture Test, Mixed Male Mitogens RNA, Viral Reverse Transcriptase Inhibitors Viral Load Viremia

Anmerkungen:	Gesehen am 22.02.2021

Umfang:	7

doi:	10.1016/s0165-2478(99)00105-4

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	1749053152

Internformat


LEADER	01000caa a2200265 4500
001	1749053152
003	DE-627
005	20230427155520.0
007	cr uuu---uuuuu
008	210222s1999 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/s0165-2478(99)00105-4 \|2 doi
035			\|a (DE-627)1749053152
035			\|a (DE-599)KXP1749053152
035			\|a (OCoLC)1341395439
040			\|a DE-627 \|b ger \|c DE-627 \|e rda
041			\|a eng
100	1		\|a Daniel, Volker \|e verfasserin \|0 (DE-588)1058939513 \|0 (DE-627)79784418X \|0 (DE-576)166309168 \|4 aut
245	1	0	\|a Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active antiretroviral treatment (HAART) in HIV-infected hemophilia patients \|c V. Daniel, C. Süsal, A. Melk, R. Weimer, M. Kröpelin, R. Zimmermann, A. Huth-Kühne, C. Uhle, G. Opelz
264		1	\|c 1999
300			\|a 7
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a Gesehen am 22.02.2021
520			\|a BACKGROUND AND OBJECTIVES: Human immunodeficiency virus (HIV)-induced immune complex load on circulating CD4+ blood lymphocytes is associated with dysfunction and depletion of CD4+ lymphocytes and with increased monocyte/macrophage function. It was investigated whether HAART reduces both the viral load in plasma and the number of immune complex-coated CD4+ lymphocytes in the blood, and whether CD4+ counts are associated with viral load and/or immune complex load. MATERIALS AND METHODS: Twelve HIV+ hemophilia patients before and after conversion to HAART (group 1); eight HIV+ hemophilia patients without antiretroviral therapy (group 2). HIV-1 RNA copies in plasma using NASBA/Nuclisens kits; CD4+ lymphocytes coated in-vivo with immune complexes using flowcytometry on whole blood samples; in-vitro responses of immune complex-coated T lymphocytes in cell culture assays. RESULTS: After conversion to HAART there was a significant reduction of viral load, CD4+ gp120+, CD4+ IgM+, and CD4+ IgG+ circulating blood lymphocytes and plasma neopterin, paralleled by a significant increase of CD4+ and CD8+ counts. The percentage of immune complex-coated CD4+ lymphocytes of converted patients was significantly associated with CD4+ counts, in-vitro responses to concanavalin A (Con A), pokeweed mitogen (PWM), phytohaemagglutinin (PHA), anti-CD3 and pooled allogeneic stimulator cells, and with plasma neopterin levels. CONCLUSION: HAART reduces viral load and HIV-induced immune complex load on circulating CD4+ blood lymphocytes. The results of this study can be interpreted to suggest that HAART increases CD4+ lymphocyte counts in part by counteracting HIV-induced autoimmune phenomena.
650		4	\|a Anti-HIV Agents
650		4	\|a Antibodies, Anti-Idiotypic
650		4	\|a Antigen-Antibody Complex
650		4	\|a Autoantibodies
650		4	\|a Autoimmunity
650		4	\|a CD4-Positive T-Lymphocytes
650		4	\|a Concanavalin A
650		4	\|a Drug Therapy, Combination
650		4	\|a Hemophilia A
650		4	\|a HIV Envelope Protein gp120
650		4	\|a HIV Infections
650		4	\|a HIV Protease Inhibitors
650		4	\|a Humans
650		4	\|a Immunoglobulins
650		4	\|a Lymphocyte Activation
650		4	\|a Lymphocyte Culture Test, Mixed
650		4	\|a Male
650		4	\|a Mitogens
650		4	\|a Reverse Transcriptase Inhibitors
650		4	\|a RNA, Viral
650		4	\|a Viral Load
650		4	\|a Viremia
700	1		\|a Süsal, Caner \|e verfasserin \|0 (DE-588)102648037X \|0 (DE-627)726772763 \|0 (DE-576)37182673X \|4 aut
700	1		\|a Melk, Anette \|e verfasserin \|0 (DE-588)1059888734 \|0 (DE-627)798960612 \|0 (DE-576)416014186 \|4 aut
700	1		\|a Weimer, Rolf \|e verfasserin \|0 (DE-588)1112293930 \|0 (DE-627)866284044 \|0 (DE-576)47650869X \|4 aut
700	1		\|a Kröpelin, M. \|e verfasserin \|4 aut
700	1		\|a Zimmermann, R. \|e verfasserin \|4 aut
700	1		\|a Huth-Kühne, A. \|e verfasserin \|4 aut
700	1		\|a Uhle, C. \|e verfasserin \|4 aut
700	1		\|a Opelz, Gerhard \|d 1944- \|e verfasserin \|0 (DE-588)1026480345 \|0 (DE-627)726772453 \|0 (DE-576)371826527 \|4 aut
773	0	8	\|i Enthalten in \|t Immunology letters \|d Amsterdam [u.a.] : Elsevier Science, 1979 \|g 69(1999), 2, Seite 283-289 \|h Online-Ressource \|w (DE-627)320508994 \|w (DE-600)2013171-9 \|w (DE-576)264627482 \|x 1879-0542 \|7 nnns
773	1	8	\|g volume:69 \|g year:1999 \|g number:2 \|g pages:283-289 \|g extent:7
856	4	0	\|u https://doi.org/10.1016/s0165-2478(99)00105-4 \|x Verlag \|x Resolving-System \|z lizenzpflichtig \|3 Volltext
856	4	0	\|u https://www.sciencedirect.com/science/article/pii/S0165247899001054 \|x Verlag \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_U
912			\|a GBV_ILN_2013
912			\|a ISIL_DE-16-250
912			\|a SYSFLAG_1
912			\|a GBV_KXP
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_121
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_647
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2018
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2043
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2050
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2056
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2116
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2158
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2193
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2472
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4277
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4346
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
912			\|a GBV_ILN_4753
936	u	w	\|d 69 \|j 1999 \|e 2 \|h 283-289 \|g 7
951			\|a AR
952			\|d 69 \|j 1999 \|e 2 \|h 283-289 \|g 7
980			\|2 2013 \|1 01 \|x DE-16-250 \|b 3869203986 \|c 00 \|f --%%-- \|d --%%-- \|e --%%-- \|j --%%-- \|y l01 \|z 22-02-21
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 00 \|s s \|a hd1999
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 01 \|s s \|0 (DE-627)1410508463 \|a wissenschaftlicher Artikel (Zeitschrift)
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 02 \|s s \|a per_9
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 03 \|s s \|a s_7
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s p \|0 (DE-627)1485025451 \|a Daniel, Volker
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s k \|0 (DE-627)1416741488 \|a Institut für Immunologie und Serologie
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s s \|a pos_1
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 05 \|s p \|0 (DE-627)1441826971 \|a Süsal, Caner
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 05 \|s k \|0 (DE-627)1416741488 \|a Institut für Immunologie und Serologie
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 05 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 05 \|s s \|a pos_2
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 06 \|s p \|0 (DE-627)1503697851 \|a Melk, Anette
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 06 \|s k \|0 (DE-627)1416741488 \|a Institut für Immunologie und Serologie
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 06 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 06 \|s s \|a pos_3
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 07 \|s p \|0 (DE-627)154650995X \|a Weimer, Rolf
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 07 \|s k \|0 (DE-627)1416741488 \|a Institut für Immunologie und Serologie
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 07 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 07 \|s s \|a pos_4
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 08 \|s p \|0 (DE-627)1441826823 \|a Opelz, Gerhard
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 08 \|s k \|0 (DE-627)1416741488 \|a Institut für Immunologie und Serologie
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 08 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 08 \|s s \|a pos_9

Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active antiretroviral treatment (HAART) in HIV-infected hemophilia patients / V. Daniel, C. Süsal, A. Melk, R. Weimer, M. Kröpelin, R. Zimmermann, A. Huth-Kühne, C. Uhle, G. Opelz

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände